Unum Group (UNM) Q1 2026 earnings review
Core Operations Resilient, But Accounting Change Masks Massive Closed Block Drag
Unum's Q1 2026 results present a tale of two companies. The core franchise is performing well, with premium income up 3.4% and an aggressive $402M share repurchase program propelling Adjusted Operating EPS up 10% YoY to $2.14. However, the reported GAAP Net Income of $1.41 per share tells the real story. Starting this quarter, management excluded the runoff 'Closed Block' segment from its adjusted operating metrics. That segment generated a massive $145.3M operating loss in Q1 (reversing from an $8.0M profit a year ago) due to long-term care policy terminations and claim incidence. While the core business is stable, the legacy risk continues to heavily weigh on the bottom line.
🐂 Bull Case
Unum accelerated its buyback program, repurchasing 5.4 million shares for $402.4M in Q1 alone, nearly double the $202.6M spent in 25Q1. This shrinking share count is a powerful driver for EPS growth.
Unum US sales surged 20.8% YoY to $335.1M, and Unum International sales grew 14.1%. The core franchise's ability to attract new business remains intact despite broader macro uncertainties.
🐻 Bear Case
The Closed Block swung to a $145.3M operating loss. While management removed this from 'adjusted' metrics to focus investors on the core business, the real cash flow and statutory impacts of this legacy long-term care drag cannot be ignored.
Claims incidence is rising in key pockets. The Unum US Group Disability benefit ratio deteriorated to 63.7% (from 61.8% YoY), and Unum UK spiked to 72.9% (from 67.1%).
⚖️ Verdict: ⚪
Neutral. The underlying core business is stable and generates exceptional cash for buybacks, but the strategic exclusion of a $145M quarterly loss in the Closed Block artificially inflates the 'adjusted' narrative.
Key Themes
Closed Block Accounting Shift Masks Collapse
Management executed a significant reporting change: removing the Closed Block from Adjusted Operating Income. This segment's operating result reversed dramatically, plummeting from an $8.0M profit in 25Q1 to a $145.3M loss in 26Q1. This was driven by elevated claim incidence and policy terminations in the Long-Term Care (LTC) line, plus lower net investment income. By moving this 'below the line,' management presents a sanitized view of earnings, but the underlying liability deterioration is a major red flag.
International Margins Decelerating Despite Strong Sales
Unum International is suffering from severe margin compression. While premium income grew a robust 16.2% YoY, segment adjusted operating income actually fell 20.2% to $30.9M. The culprit is Unum UK, where the benefit ratio spiked from 67.1% in 25Q1 to 72.9% in 26Q1 due to higher average claim sizes and increased incidence in the group long-term disability line.
Group Disability Margin Drift
The core profit engine, Unum US Group Disability, saw its operating income drop 10.6% YoY to $106.6M. The benefit ratio is decelerating (worsening), moving up to 63.7% from 61.8% a year ago. Management attributed this to pricing actions and higher claim incidence in the short-term disability product line. This confirms the long-term headwind management previously guided regarding the normalization of disability margins.
Capital Return Program Accelerating
Unum is aggressively shrinking its share count, acting as the primary driver for EPS growth. In 26Q1, the company repurchased $402.4M of stock (5.4 million shares), doubling the $202.6M pace of 25Q1. Coupled with a resilient holding company liquidity of $1.7 billion and an RBC ratio of ~460%, Unum has ample runway to continue digesting shares.
Group Life & AD&D Turnaround
A notable bright spot offsetting Disability weakness was the Group Life and AD&D segment. Adjusted operating income surged 66.3% YoY to $115.1M. This was driven by a sharp improvement in the benefit ratio, which dropped to 61.8% from 69.3% in 25Q1, reflecting lower claim incidence and higher net investment income yields.
Other KPIs
Accelerating. Up 10.5% YoY, driven by stable persistency (78.1%) and a favorable benefit ratio improvement to 46.0% (down from 47.7% in 25Q1) due to better experience in life, cancer, and critical illness lines.
Accelerating. A robust 20.8% YoY growth compared to $277.5M in 25Q1. This growth was broad-based, with the Core Market (<2,000 employees) up 31.9% and Supplemental/Voluntary sales up 19.7%.
Stable compounding growth. Represents a 3.6% increase YoY ($76.17 in 25Q1). Total Stockholders' Equity remains solid at $10.9 billion.
Guidance
Stable/Accelerating. The guidance range was reaffirmed, representing approximately 8% to 12% growth. Crucially, this growth is benchmarked against a 'redefined' FY25 base of $7.93, which removes the Closed Block results to align with the new reporting structure. Hitting this target relies heavily on the continued execution of the aggressive share repurchase program and stabilization in Group Disability incidence.
Key Questions
Closed Block Terminal Trajectory
With the Closed Block now completely excluded from adjusted metrics and posting a severe $145M operating loss in Q1, what is the cash flow and statutory capital expectation for this segment for the remainder of FY26? Are the underlying LTC incidence trends worsening structurally?
Unum UK Claims Shock
The UK benefit ratio spiked nearly 600 basis points YoY. Is this higher average claim size and incidence an anomaly tied to Q1 seasonality, or are we seeing a structural shift in the UK group disability risk pool?
Short-Term Disability Deterioration
You cited higher incidence in the short-term disability product line as a driver for the Unum US margin compression. Is this localized to specific industries or geographies, and how is pricing keeping up with this specific frequency trend?